Every biotech organization has a unique path to progress. For Anixa Biosciences, Inc., that path is built on outsourcing to trusted external partners that collaborate with a lean, dynamic internal team.
In this insightful interview with Louis Garguilo, Chief Editor of Outsourced Pharma, Anixa’s CEO, Amit Kumar, PhD, shares why he and his team chose Cytovance Biologics. Amit highlights Cytovance as the right CDMO partner, with the microbial expertise, proven commercial execution, and long-term partnership mindset needed to advance the company’s breast cancer vaccine through the next phases of development.
We’re proud to serve as Anixa’s integrated drug substance manufacturing partner, providing process development, analytical services, and scalable cGMP production to help move this promising program toward its next milestone.
Read the full interview here.